Radafaxine
Clinical data | |
---|---|
Other names | (S,S)-Hydroxybupropion; (2S,3S)-Hydroxybupropion; GW-353,162 |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Radafaxine (developmental code GW-353,162; also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropionGlaxoSmithKline in the 2000s for a variety of different indications but was never marketed.[2] These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity.[2] Regulatory filing was planned for 2007,[3] but development was discontinued in 2006 due to "poor test results".[4]
Pharmacology
Pharmacodynamics
Radafaxine is described as a
abuse potential similar to bupropion.[8]
Chemistry
Radafaxine is a potent
Wellbutrin. More specifically, "hydroxybupropion" is an analogue of bupropion, and radafaxine is an isolated isomer ((2S,3S)-) of hydroxybupropion.[9] Therefore, radafaxine builds on at least some of the properties of bupropion in humans.[3] Another analogue of bupropion, manifaxine (GW-320,659), was derived from radafaxine and was also studied.[10]
See also
References
- PMID 24484978.
- ^ a b "Radafaxine - AdisInsight".
- ^ a b "Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum". BioSpace. 23 November 2004. Archived from the original on 2007-09-28.
- ^ Kollewe J (27 July 2006). "GSK breakthrough on bird flu vaccine". Independent.co.uk. Archived from the original on 2007-10-01.
- PMID 17167747.
- PMID 12909199.
- ^ Burch D. "Neurosciences Development Portfolio" (PDF). Archived from the original (PDF) on 2007-09-28.
- S2CID 13313064.
- ^ Radafaxine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ "Manifaxine - AdisInsight".
External links
- Media related to Radafaxine at Wikimedia Commons